Min Kang is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
420 Mcphee Rd SW
Suite A
Olympia, WA 985025014
Telephone
360-352-2900Provider last certified this registry record 6 Sept 2024.
Clinical trials
- Impacted Tooth Management and Osteoradionecrosis Risk in NPC
Sponsor: First Affiliated Hospital of Guangxi Medical University
- Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
Sponsor: Addpharma Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20259 payments
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- BeOne Medicines USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
60.3%RANK Ligand Inhibitor60%Denosumab100%Part B, office-administered≥105 patientsBisphosphonate0.3%Zoledronic acid100%Part B, office-administered≥12 patientsBlood & clotting
20%Erythropoiesis-stimulating Agent9.9%Epoetin alfa100%Part B, office-administered≥11 patientsIron, parenteral preparations9.8%Ferric derisomaltose100%Part B, office-administered≥17 patients+ 1 more class in this area
Sensory organs
6.8%Corticosteroid6.8%Dexamethasone sodium phosphate100%Part B, office-administered≥39 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”